In mouse studies, the drug was found to delay the growth of tumors and enhance the sensitivity of glioblastoma cells to anticancer treatments.
Due to its highly aggressive and lethal nature, glioblastoma, a type of brain cancer, is often resistant to traditional treatments. As a result, researchers are seeking out characteristics of glioblastoma cells that could point to potential targets for drug development.
One such characteristic is the dependence of the cells on de novo lipid synthesis, also known as the conversion of carbohydrates to fats, to meet their energy needs.
New research led by scientists at Massachusetts General Hospital (MGH), a founding member of Mass General Brigham, reveals that a drug that inhibits the enzyme stearoyl CoA Desaturase 1 (SCD) interferes with this process, and when administered to mice with glioblastoma, the drug delays tumor growth and increases glioblastoma cells’ sensitivity to anticancer therapies. The findings, which are published in Science Translational Medicine, may lead to new treatment options for patients.
In this new research, the team tested the anti-glioblastoma potential of an SCD inhibitor, YTX-7739, that can cross the blood-brain barrier and is being evaluated as an oral drug in phase I clinical trials for the treatment of patients with Parkinson’s disease.
The investigators found that YTX-7739 was toxic to patient-derived glioblastoma stem cells. By blocking SCD, the cells accumulated too many saturated fatty acids, a process referred to as lipotoxicity. Also, when administered to mice with tumors, YTX-7739 inhibited processes involved in fatty acid metabolism in glioblastoma cells and increased the cells’ sensitivity to conventional glioblastoma chemotherapy.
When examining the detailed mechanisms behind YTX-7739’s effects on cells, the scientists found that the MEK/ERK signaling pathway renders glioblastoma cells particularly vulnerable to YTX-7739, whereas the AMPK signaling pathway acts to protect glioblastoma cells and can make them resistant to the loss of de novo lipid synthesis that occurs when YTX-7739 is present.
“Based on our results, we propose that MEK/ERK and AMPK activities, which can be detected in tumor biopsies, could be predictive biomarkers to guide patient selection and stratification,” says Badr.
In other words, patients whose tumors have robust MEK/ERK activity would likely benefit from therapies such as YTX-7739, whereas those with high AMPK activity likely would not. “Our findings should also help tailor treatment paradigms to maximize therapeutic efficacy.
For instance, some widely used drugs, such as the anti-inflammatory agent salicylate or the anti-diabetic compound metformin, are potent activators of AMPK and could be detrimental to the efficacy of YTX-7739 or other de novo lipid synthesis–targeting therapies,” says Badr.
News
Antibody engineering drives innovation in drug development
Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound [...]
Breakthrough Study Reveals How Bladder Cancer Starts and Spreads
Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal circular DNA in tumor cells drives resistance to therapy. These discoveries open new therapeutic avenues. A groundbreaking study led by [...]
AI and Quantum Mechanics Accelerate Drug Discovery
A recent article published in the Journal of Chemical Information and Modeling researchers at Southern Methodist University (SMU) have developed SmartCADD, an open-source virtual tool designed to speed [...]
Targeting ‘undruggable’ diseases: Researchers reveal new levels of detail in targeted protein degradation
Researchers at the University of Dundee have revealed in the greatest detail yet the workings of molecules called protein degraders which can be deployed to combat what have previously been regarded as "undruggable" diseases, [...]
Revolutionizing Virology: AI Discovers Over 160,000 New RNA Viruses
Largest discovery of new virus species sheds light on the hidden virosphere. Artificial intelligence (AI) has been used to reveal details of a diverse and fundamental branch of life living right under our feet and in every [...]
Cardiac Crisis: COVID-19 Doubles Risk of Heart Attacks, Strokes, and Death
Research indicates that COVID-19 survivors face doubled risks of severe cardiac events for years after recovery, especially if hospitalized. People with A, B, or AB blood types are particularly vulnerable, highlighting the need for personalized approaches [...]
AI steps into science limelight with Nobel wins
For long periods of its history, artificial intelligence has lurked in the hinterland of science, often unloved and unfunded—but two Nobel prizes in one week suggest its time in the sunshine has finally arrived. [...]
MIT Scientists Shed New Light on the Critical Brain Connections That Define Consciousness
A new study provides further evidence that consciousness depends on communication between the brain’s sensory and cognitive regions in the cortex. Our brains are constantly making predictions about our surroundings, enabling us to focus [...]
Common Chemicals Found in Shampoo and Plastic Could Be Quietly Disrupting Your Heart’s Rhythm
UC study of Fernald data links environmental phenols to heart toxicities Environmental phenols are present in numerous everyday consumer products, serving as preservatives in packaged foods, parabens in shampoos, and bisphenol A (BPA) in [...]
Revolutionary Brain Tech Offers New Hope for Stroke and Injury Recovery
University of Pittsburgh researchers report that deep brain stimulation (DBS) can effectively enhance motor functions in individuals with arm and hand paralysis due to brain injuries, with promising results from early human and monkey [...]
NIH Scientists Discover Gene Responsible for Rare Eye Disease
Findings supported by the NIH pave the way for the development of genetic testing, clinical trials, and therapies. Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a gene linked to certain [...]
Alzheimer’s Breakthrough: Synthetic THC Pill Proves Effective in Clinical Trial
Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer’s agitation medications. A study conducted by researchers from Johns Hopkins University School of Medicine and Tufts University School of Medicine found that a pill form [...]
The Future of Rare Disease Treatment with Precision Medicine
Understanding rare diseases Rare diseases affect less than 5 people out of 10,000. However, this still amounts to about 7% of the world’s population, with over 10,000 such conditions. Almost all are genetic in [...]
Doctors issue warning for upcoming ‘tripledemic
The term ‘tripledemic’ has hit headlines this week as the NHS begins its Covid and fluvaccine roll-out for vulnerable adults. As the cold weather sets in, many of us have experienced a decline in health, and this may [...]
The FDA approved a gel that can stop bleeding from wounds in seconds
Aug 15 (Reuters) - The U.S. Food and Drug Administration has cleared Cresilon's gel to quickly control bleeding, the privately held company said on Thursday, potentially giving emergency medical technicians and combat medics a [...]
High levels of microplastics found in prostate tumors, possibly linked to take-out food
The presence of microplastics in prostate tumors points to potential health risks, and researchers are calling for urgent studies to explore how take-out food may be driving this exposure. In a recent study published [...]